



LEGAL CONTRACTS BETWEEN PATIENTS, PHARMA AND RESEARCHERS – WHERE ARE WE AND WHAT IS MISSING?

Description

Legal agreements for collaboration between pharmaceutical industry and patients and patient organisations has historically been experienced as problematic one-sided by the patient community for multiple reasons. In order to create the conditions for increasing collaborations, this legal barrier is addressed across the Atlantic by several collaborating organisations and multistakeholder partnerships.

This interactive session will give you the insights to the issues experienced by the patient community, present the co-created solutions from collaborative initiatives such as WECAN (Workgroup of European Cancer Advocacy Network), PFMD (Patient Focused Medicines Development) and The National Health Council (NHC) together with the pharma industry. In this session you will also learn about the tools and resources that have been co-created with pharma and patient organisations.

By joining this session, you will;

- Learn about and experience first hand the root causes of the issue
- Learn about the different collaborative initiatives and their solutions to tackle the problem
- Experience the issue and put into practice the co-created reference agreement on Patient Advisory Board collaborations
- Help shape the future legal toolkit to help patients make the most of the legal language in the co-created reference contracts